Customizing inhaled therapy to meet the needs of COPD patients. Postgrad Med ... Prime single-dose device (e.g., Foradil Aerolizer, Spiriva Handihaler) by piercing capsule.

But sales of Spiriva, approved in chronic obstructive pulmonary disease and asthma ... and Avillion's first-in-class asthma rescue inhaler Airsupra has been halted early after the drug ...

Chronic obstructive pulmonary disease (COPD ... They are also used as add-on therapy for asthma maintenance in the case of Spiriva. There is also a combination inhaler called Combivent that contains ...

With COPD, you have lung damage that worsens over time. Trelegy Ellipta does not come as a generic drug. Trelegy Ellipta comes in a dry powder inhaler. Each active ingredient in Trelegy Ellipta ...

Patients with asthma and COPD routinely switch from pressurized metered-dose inhalers to dry powder inhalers and vice versa.

COPD requires regular monitoring through tests like spirometry to assess the condition’s severity and aid in an individualized treatment plan. COPD is a progressive lung condition that makes ...

The US Food and Drug Administration has approved dupilumab as an add-on maintenance therapy for adults whose chronic obstructive pulmonary disease (COPD) is inadequately controlled with inhaler ...

Two posters presented at the CHEST 2024 annual meeting underscore the importance of early identification and treatment of ...

Current guidelines advocate for using inhaled medicines across all stages of disease severity. These drugs, which open airways and reduce swelling, are a cornerstone of COPD treatment, making ...

Among patients with chronic obstructive pulmonary disease who received prior treatment with multiple-inhaler triple therapy, single-inhaler triple therapy was effective in improving health status ...

Triple therapy inhalers for COPD can reduce exacerbations but may increase pneumonia risk, necessitating careful patient phenotype assessment. Roflumilast and azithromycin effectively reduce COPD ...

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) to reduce COPD exacerbations in some patients whose symptoms aren’t adequately controlled with inhaled medicines.